423 related articles for article (PubMed ID: 32561716)
1. Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells.
Chen Y; Liu J; Zhi S; Zheng Q; Ma W; Huang J; Liu Y; Liu D; Liang P; Songyang Z
Nat Commun; 2020 Jun; 11(1):3136. PubMed ID: 32561716
[TBL] [Abstract][Full Text] [Related]
2. Characterization and applications of Type I CRISPR-Cas systems.
Hidalgo-Cantabrana C; Barrangou R
Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
[TBL] [Abstract][Full Text] [Related]
3. Multiplexed conditional genome editing with Cas12a in
Port F; Starostecka M; Boutros M
Proc Natl Acad Sci U S A; 2020 Sep; 117(37):22890-22899. PubMed ID: 32843348
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Directed Gene Editing Catalyzes Precise Gene Segment Replacement
Sansbury BM; Wagner AM; Tarcic G; Barth S; Nitzan E; Goldfus R; Vidne M; Kmiec EB
CRISPR J; 2019 Apr; 2():121-132. PubMed ID: 30998096
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9.
Yan F; Wang W; Zhang J
Cell Biol Toxicol; 2019 Dec; 35(6):489-492. PubMed ID: 31468291
[No Abstract] [Full Text] [Related]
6. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
[TBL] [Abstract][Full Text] [Related]
7. Fragmentation of the CRISPR-Cas Type I-B signature protein Cas8b.
Richter H; Rompf J; Wiegel J; Rau K; Randau L
Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2993-3000. PubMed ID: 28238733
[TBL] [Abstract][Full Text] [Related]
8. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
Xu R; Wei P; Yang J
Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
[TBL] [Abstract][Full Text] [Related]
9. Requirements for Pseudomonas aeruginosa Type I-F CRISPR-Cas Adaptation Determined Using a Biofilm Enrichment Assay.
Heussler GE; Miller JL; Price CE; Collins AJ; O'Toole GA
J Bacteriol; 2016 Nov; 198(22):3080-3090. PubMed ID: 27573013
[TBL] [Abstract][Full Text] [Related]
10. Multiplexed Genome Engineering with Cas12a.
Weisbach NR; Meijs A; Platt RJ
Methods Mol Biol; 2021; 2312():171-192. PubMed ID: 34228291
[TBL] [Abstract][Full Text] [Related]
11. Keeping our eyes on CRISPR: the "Atlas" of gene editing.
Wang W; Hou J; Zheng N; Wang X; Zhang J
Cell Biol Toxicol; 2019 Aug; 35(4):285-288. PubMed ID: 31165372
[No Abstract] [Full Text] [Related]
12. Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing.
Xu X; Chemparathy A; Zeng L; Kempton HR; Shang S; Nakamura M; Qi LS
Mol Cell; 2021 Oct; 81(20):4333-4345.e4. PubMed ID: 34480847
[TBL] [Abstract][Full Text] [Related]
13. CRISPR RNA and anti-CRISPR protein binding to the
Hong S; Ka D; Yoon SJ; Suh N; Jeong M; Suh JY; Bae E
J Biol Chem; 2018 Feb; 293(8):2744-2754. PubMed ID: 29348170
[TBL] [Abstract][Full Text] [Related]
14. CRISPR-Cas12a System for Biosensing and Gene Regulation.
Shi Y; Fu X; Yin Y; Peng F; Yin X; Ke G; Zhang X
Chem Asian J; 2021 Apr; 16(8):857-867. PubMed ID: 33638271
[TBL] [Abstract][Full Text] [Related]
15. A Type I-F Anti-CRISPR Protein Inhibits the CRISPR-Cas Surveillance Complex by ADP-Ribosylation.
Niu Y; Yang L; Gao T; Dong C; Zhang B; Yin P; Hopp AK; Li D; Gan R; Wang H; Liu X; Cao X; Xie Y; Meng X; Deng H; Zhang X; Ren J; Hottiger MO; Chen Z; Zhang Y; Liu X; Feng Y
Mol Cell; 2020 Nov; 80(3):512-524.e5. PubMed ID: 33049228
[TBL] [Abstract][Full Text] [Related]
16. CRISPR as a strong gene editing tool.
Shen S; Loh TJ; Shen H; Zheng X; Shen H
BMB Rep; 2017 Jan; 50(1):20-24. PubMed ID: 27616359
[TBL] [Abstract][Full Text] [Related]
17. Crystal Structures of Csm2 and Csm3 in the Type III-A CRISPR-Cas Effector Complex.
Takeshita D; Sato M; Inanaga H; Numata T
J Mol Biol; 2019 Feb; 431(4):748-763. PubMed ID: 30639408
[TBL] [Abstract][Full Text] [Related]
18. More specific CRISPR editing.
de Souza N
Nat Methods; 2014 Jul; 11(7):712. PubMed ID: 25110782
[No Abstract] [Full Text] [Related]
19. Novel Type V-A CRISPR Effectors Are Active Nucleases with Expanded Targeting Capabilities.
Aliaga Goltsman DS; Alexander LM; Devoto AE; Albers JB; Liu J; Butterfield CN; Brown CT; Thomas BC
CRISPR J; 2020 Dec; 3(6):454-461. PubMed ID: 33146573
[TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.
O'Connell MR
J Mol Biol; 2019 Jan; 431(1):66-87. PubMed ID: 29940185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
